Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials - Wikidata - wikimedia - TriplyDB

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

http://www.wikidata.org/entity/Q26778276

about

Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project New ethical considerations in vaccine trials.Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign.Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia.Research on Controlled Drug Use: A Paradigm for Public Health Research in Sustainable Health

P2860

Q26778266-0A3C70B0-CCA2-49A5-8458-F7E43D5047D8 Q26778270-5A890855-126A-4350-B1AA-B6D613F067C7 Q28598111-CF700F21-8D94-41DF-8D86-D9710D3011FC Q39261826-144EDC33-AF89-4835-AFA5-493DE617F8E3 Q43923897-1811282D-95B5-4AA0-8B12-A94EDE69DEE1 Q52684550-6F6C50FF-8FF1-460E-9DFA-1E84C759E70D Q57988632-DD355E1A-B880-431D-BD1D-065268EA4F78

P2860

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

http://www.wikidata.org/entity/Q26778276

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@ast

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@en

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@nl

type

label

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@ast

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@en

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@nl

prefLabel

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@ast

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@en

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@nl

P1433

Q26778276-014D9F99-124B-4A38-BBF6-59409659031C

P1476

Q26778276-3EB0EAB2-1968-4A2C-BEF2-DBD88445D29D

P2093

Q26778276-0C58F27B-EB6A-4D4E-A1D6-4BAAAF68ADCC

Q26778276-24EF1775-C93E-4D62-AF07-FCA187CC5FA3

Q26778276-62D1C32F-3F66-42AD-9300-977A85262905

Q26778276-72F4DA9C-D834-4F11-A5CE-D1B71A5859A7

Q26778276-847188C7-1C4B-4EDC-992E-5F1378F00E0B

Q26778276-848CD9D7-6885-49BE-8127-83A56E27A701

Q26778276-974C8C40-D9F4-46C2-AC96-54BF9164DB6A

Q26778276-DA908F5D-CAF4-41AC-8AEE-DA3A992792E6

Q26778276-FBDC8573-9009-4AD1-9D41-FF738B227B3E

Q26778276-FE7985CA-2581-4A19-896D-2DA5616E0F33

P275

Q26778276-BC54D5C3-C797-4E17-83E1-BCA71ABBDA79

P2860

Q26778276-120EB4CE-CD08-4A33-9572-3BFAD6DEB878

Q26778276-1634785C-38CF-442D-9239-9E56517E737E

Q26778276-1E5C5BAF-1FC8-44EF-BB33-A76FAE86608B

Q26778276-2293188B-5F17-45F0-8732-8A73D8AA104D

Q26778276-2B8E7F17-1D21-464A-97EA-C329948FFF3E

Q26778276-60A30C39-88BA-4BC4-9717-FD6F2CAEB257

Q26778276-7354A950-1D83-47C1-BA82-18640F8A257F

Q26778276-7B9DB865-4E40-4845-91A6-5768EB7862CE

Q26778276-830102B5-B7A5-4227-811A-574576EC4DAB

Q26778276-845EFE5C-257A-416B-9957-0C4FABFBCD99

P304

Q26778276-62C49EE4-0F32-42B9-BA4F-3224CD341DB9

P31

Q26778276-27F62400-8CA5-421C-A353-1C69245A655A

Q26778276-C75F6420-D7D3-45C8-BC51-CB790AF529ED

P3181

Q26778276-59FB96BC-017D-4C33-85FD-B6356B540825

P356

Q26778276-CA2F4E76-F1C5-4FD4-AA5E-513B80E75296

P407

Q26778276-A360D573-DCC3-4DC6-8F2F-A8291AAAD86C

P433

Q26778276-5C9E1EE2-430A-487E-8C92-5AFD6FC403FE

P478

Q26778276-65746B6B-47B9-4182-AFE3-36E78BEBA3A1

P50

Q26778276-05976958-81FF-4344-8649-04EBEAA16A7E

Q26778276-87A886A7-6F43-4789-8ECA-504759A7DC86

P5008

Q26778276-5327D41B-2A99-4D8B-BBAD-AAB73E215A63

P577

Q26778276-88827CEA-BE80-403D-99F1-444D534CA15D

P5875

Q26778276-C385D23C-15B6-47B4-9AF2-C77E72FD9893

P698

Q26778276-BA1A928B-5EE4-45ED-A428-C6405A479B0A

P921

Q26778276-FEBCDE0C-EE1C-4E3F-ABD4-CEC007288811

P932

Q26778276-DC10A529-1682-4DD7-8BB9-ADEB4D06598C

P3181

P356

P1433

Clinical Infectious Diseases

P1476

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials

@en

P2093

Adebayo Akinsola

http://www.w3.org/2001/XMLSchema#string

Aldiouma Diallo

http://www.w3.org/2001/XMLSchema#string

Beate Kampmann

http://www.w3.org/2001/XMLSchema#string

Bou Diarra

http://www.w3.org/2001/XMLSchema#string

Enricke Bouma

http://www.w3.org/2001/XMLSchema#string

Fadima Cheick Haidara

http://www.w3.org/2001/XMLSchema#string

Godwin C Enwere

http://www.w3.org/2001/XMLSchema#string

Marie-Pierre Preziosi

http://www.w3.org/2001/XMLSchema#string

Olubukola T Idoko

http://www.w3.org/2001/XMLSchema#string

Patrick Odum Ansah

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons

Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa

Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine

Impact, challenges, and future projections of vaccine trials in Africa

Procedures of recruiting, obtaining informed consent, and compensating research participants in Qatar: findings from a qualitative investigation

Negative rumor: contagion of a psychiatric department

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Profile of the Navrongo Health and Demographic Surveillance System.

P304

S416-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5003287

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/CID/CIV596

http://www.w3.org/2001/XMLSchema#string

P407

P433

suppl 5

http://www.w3.org/2001/XMLSchema#string

P478

61 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P50

Abraham Hodgson

P5008

P577

2015-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283648769

http://www.w3.org/2001/XMLSchema#string

P698

26553669

http://www.w3.org/2001/XMLSchema#string

P921

meningococcal meningitis

P932

4639498

http://www.w3.org/2001/XMLSchema#string